ELCC 2019 | Molecularly-guided treatment of advanced NSCLC: ALK inhibitor sequencing

Alice Tsang Shaw

Alice Tsang Shaw, MD, PhD, Massachusetts General Hospital, Boston, MA, discusses the importance of screening for genetic alterations when treating patients with advanced non-small cell lung cancer (NSCLC). She explains how the sequencing of ALK inhibitors could be molecularly guided. This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Share this video